Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MTNB

Matinas Biopharma (MTNB)

Matinas Biopharma Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:MTNB
DateTimeSourceHeadlineSymbolCompany
05/16/20247:00AMGlobeNewswire Inc.New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024AMEX:MTNBMatinas Biopharma Holdings Inc
05/09/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
05/09/20244:05PMGlobeNewswire Inc.Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
05/09/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:MTNBMatinas Biopharma Holdings Inc
05/07/20248:00AMGlobeNewswire Inc.Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingAMEX:MTNBMatinas Biopharma Holdings Inc
05/02/20247:00AMGlobeNewswire Inc.Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024AMEX:MTNBMatinas Biopharma Holdings Inc
04/30/20248:00AMGlobeNewswire Inc.In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyAMEX:MTNBMatinas Biopharma Holdings Inc
04/03/20248:30AMGlobeNewswire Inc.Matinas BioPharma Prices $10 Million Registered Direct OfferingAMEX:MTNBMatinas Biopharma Holdings Inc
03/27/20244:05PMGlobeNewswire Inc.Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
03/25/20248:00AMGlobeNewswire Inc.Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationAMEX:MTNBMatinas Biopharma Holdings Inc
03/22/20249:15AMGlobeNewswire Inc.Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseAMEX:MTNBMatinas Biopharma Holdings Inc
03/22/20246:30AMGlobeNewswire Inc.Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsAMEX:MTNBMatinas Biopharma Holdings Inc
02/26/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
02/26/20248:00AMGlobeNewswire Inc.Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionAMEX:MTNBMatinas Biopharma Holdings Inc
02/20/20247:35AMEdgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
02/20/20247:30AMGlobeNewswire Inc.Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisAMEX:MTNBMatinas Biopharma Holdings Inc
01/09/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
01/03/20247:00AMGlobeNewswire Inc.Matinas BioPharma to Present at Biotech Showcase 2024AMEX:MTNBMatinas Biopharma Holdings Inc
12/27/20237:40AMEdgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
12/27/20237:30AMGlobeNewswire Inc.Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesAMEX:MTNBMatinas Biopharma Holdings Inc
12/21/20237:40AMEdgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
12/21/20237:30AMGlobeNewswire Inc.Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
12/15/20239:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
 Showing the most relevant articles for your search:AMEX:MTNB